EE371 Treatment Patterns, Healthcare Resource Use, and Costs Among US Patients With Epidermal Growth Factor Receptor Mutated (EGFRm) Metastatic Non-Small Cell Lung Cancer (mNSCLC) After Discontinuation of Osimertinib
Jun 1, 2024, 00:00
10.1016/j.jval.2024.03.668
https://www.valueinhealthjournal.com/article/S1098-3015(24)00783-6/fulltext
Title :
EE371 Treatment Patterns, Healthcare Resource Use, and Costs Among US Patients With Epidermal Growth Factor Receptor Mutated (EGFRm) Metastatic Non-Small Cell Lung Cancer (mNSCLC) After Discontinuation of Osimertinib
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(24)00783-6&doi=10.1016/j.jval.2024.03.668
First page :
Section Title :
Open access? :
No
Section Order :
10141